DOH Abu Dhabi and Sanofi plan vaccine centre with 5 capabilities for UAE clinics

Department of Health Abu Dhabi (DOH Abu Dhabi) and Sanofi signed a 23 June 2026 memorandum of understanding to explore a Vaccine Innovation Centre in Abu Dhabi, a move that could shorten the distance between vaccine research, clinical development and UAE patient access.

For Dubai clinics regulated by the Dubai Health Authority (DHA), the announcement is less about immediate stock changes and more about procurement, coding and patient demand. For Abu Dhabi providers, it sits under the regulator that controls licensing, research governance and insurance claims. For northern emirates operators, the relevant public pathway remains Ministry of Health and Prevention (MOHAP) and Emirates Health Services, especially for preventive and travel vaccination.

What DOH Abu Dhabi and Sanofi agreed

The DOH Abu Dhabi release said the MoU will advance vaccine innovation and jointly explore a Vaccine Innovation Centre in Abu Dhabi. The centre is planned within Abu Dhabi's Health, Endurance, Longevity and Medicine (HELM) Cluster, which is backed by the Abu Dhabi Investment Office. The announcement was made during the BIO International Convention 2026 in San Diego, United States.

The proposed centre has five named capability areas that matter to operators:

• AI-enabled vaccine discovery and design
• Immunology
• Clinical development
• mRNA research
• Clinical manufacturing

DOH Abu Dhabi said the agreement builds on a 2025 strategic partnership with Sanofi. In the 2025 release, DOH Abu Dhabi said the collaboration would cover clinical research planning, manufacturing preparedness and knowledge sharing. The 2026 update moves the story toward a physical innovation centre, subject to the parties moving from MoU to a fuller agreement.

“bringing together AI, scientific research, clinical expertise, advanced manufacturing and enabling regulation”
— H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary, DOH Abu Dhabi

Why clinics and insurers should care

The highest-stakes readers are clinic COOs, CFOs and medical directors. COOs need to know whether new vaccines require cold-chain changes, staff training or registry reporting. CFOs need to know whether vaccines are reimbursed through payer contracts or sold as cash preventive services. Medical directors need to know whether trials, post-marketing surveillance or eligibility rules change local clinical practice.

No public DOH Abu Dhabi release gave a launch date, capital budget, product pipeline or patient eligibility rules for the centre. That limits what clinics can implement today. The practical step is to audit current vaccination workflows before new products arrive: storage logs, consent forms, batch documentation, adverse event reporting and payer pre-approval rules.

Price discipline also matters. Public prices differ by emirate and service type. Emirates Health Services lists travel vaccine fees such as AED 50 for typhoid, AED 120 for yellow fever, AED 75 for meningococcal polysaccharide vaccine, AED 100 for meningococcal conjugate vaccine and AED 150 per dose for hepatitis A in its public service material. Private clinic prices can be higher, but operators should quote from their own approved tariff, stock cost and insurer contract, rather than copying public-sector fees.

For insurers, the pressure point is benefit design. Daman and Thiqa are central to Abu Dhabi coverage. Sukoon is relevant for many Dubai employer plans. Coverage for adult preventive vaccination, travel vaccination and newer products is plan-specific. Claims teams should check whether vaccine material and administration are billed separately, whether pre-approval is needed, and whether the patient meets age, risk or travel criteria.

What patients may see next

Patients should expect no immediate change at the clinic counter from this MoU alone. DHA, DOH Abu Dhabi and MOHAP still set the local rules for licensed providers in their jurisdictions. New vaccine availability will depend on registration, procurement, clinical guidance, payer coverage and clinic stock.

Dubai remains the first market many private providers watch because of patient volume and employer insurance demand. Abu Dhabi has the research and regulatory angle in this announcement. Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain will depend on MOHAP and EHS pathways, plus private provider uptake.

Clinic leaders should watch for four next signals: a signed centre agreement after the MoU, a public site or operating partner, named vaccine programmes, and any DOH Abu Dhabi circular on research participation or reporting. Patients looking for licensed clinics can use the UAE Open Healthcare Directory to compare providers across Dubai, Abu Dhabi, Al Ain, Sharjah, Ajman, Ras Al Khaimah, Fujairah and Umm Al Quwain.